Nycomed and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast (Daxas^®). Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

• Strong growth of Key Products and in emerging markets. Impact of pantoprazole's patent expiry in May 2009 as expected.
• Total net turnover decreased 7.6% (-8.9% in local currencies) to €776.4 million (Q1/2009: €839.9 million).
• Adjusted EBITDA decreased 24.1% (-24.8% in local currencies) to €233.1 million (Q1/2009: €307.0 million).
• Daxas^® (roflumilast) is advancing: Nycomed received a positive opinion from CHMP an

• Joint venture shows commitment to growth in Russia & CIS

• Partners optimize distribution model for key market